

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number  
**WO 2004/030690 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/17,**  
**A61P 9/10**

(21) International Application Number:  
**PCT/NZ2003/000222**

(22) International Filing Date: 3 October 2003 (03.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
521955 4 October 2002 (04.10.2002) NZ

(71) Applicant (for all designated States except US): **A2 COR-**  
**PORATION LIMITED [NZ/NZ]; c/- Edinburgh Trust,**  
Level 10, 475 Moray Place, Dunedin (NZ).

(72) Inventor: **McLACHLAN, Corran, Norman, Stuart (de-**  
ceased).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CAMPBELL,**

**Julie, Hazel [AU/AU]; 181 Savages Road, Brookfield,**  
**QLD 4069 (AU). TAILFORD, Kristy, Ann [AU/AU];**  
15 Dalwood Street, Carseldine, Queensland 4034 (AU).  
**MCLACHLAN, Ulrike** (heirress of the deceased inventor)  
[—/—]; 29 Summer Street, Devonport, Auckland (NZ).

(74) Agent: **BALDWIN SHELSTON WATERS;** Level 14,  
342 Lambton Quay, Wellington (NZ).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: THERAPEUTIC USES OF  $\beta$ -CASEIN A<sup>2</sup> AND DIETARY SUPPLEMENT CONTAINING  $\beta$ -CASEIN A<sup>2</sup>

A.




Table of Significance (P<0.05)

Group	Is significantly different from Group
1	3, 4, 5
2	1, 5, 8, 10
3	1, 5, 8, 10
4	1, 5, 8, 10
5	1, 5, 8, 10
6	3, 4, 5
7	3, 4, 5
8	3, 4, 5
9	1, 5, 8, 10
10	3, 4, 5

(57) **Abstract:** A method of reducing the serum level in a mammal of any one more cholesterol, low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, apolipoprotein B, and triglycerides by the ingestion of a composition containing  $\beta$ -casein A<sup>2</sup>. A dietary supplement formed by the addition of  $\beta$ -casein to a food or drink for human consumption where the  $\beta$ -casein is comprised of at least 95%  $\beta$ -casein A<sup>2</sup>, preferably solely  $\beta$ -casein A<sup>2</sup>.



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*